Institution
Institut universitaire du cancer de Toulouse Oncopole
Recent research
- Health & MedicineOpen access
Abstract Background: Informed consent is a cornerstone of ethical clinical research. However, the increasing length and complexity of information and consent forms (ICFs) raise concerns about their effectiveness in ensuring truly informed participation. This study examined the ro...
- AI & ComputingOpen access
Abstract Background Accurate biomarkers for prognosis and selection of patients most likely to benefit from neoadjuvant chemoimmunotherapy in early breast cancer (eBC) are urgently needed. The Immune Constant of Rejection (ICR) gene expression signature, a 20-gene signature refle...
- BiologyOpen access
Hackathon on predictive modelling in systems pharmacology: design, implementation, and outcomes
Background The growing availability of multi-omics data and machine learning methods creates both an opportunity and a challenge for the systems pharmacology community: the opportunity to model drug action at unprecedented mechanistic resolution, and the challenge of equipping a...
- BiologyOpen access
PI3Kδ is selectively inhibited by roginolisib by stabilizing the C-terminal helix kα12
Abstract Phosphoinositide 3-kinases (PI3Ks) are major regulators of cell growth, proliferation and signalling, constituting key therapeutic targets in cancer, inflammation, and other diseases. Individual class I PI3K isoforms control key cellular functions, imposing the need to g...
- Health & MedicineOpen access
Isatuximab–bortezomib–lenalidomide–dexamethasone (Isa-VRd) has emerged as a standard of care for newly diagnosed multiple myeloma transplant-ineligible patients. A subcutaneous (SC) formulation of isatuximab delivered via an on-body injector (OBI) has been developed to facilitate...
- Health & MedicineOpen access
Background In classic Hodgkin lymphoma (cHL), identifying high-risk patients is crucial for tailored treatment. Clinical risk factors are useful, but there is room for improvement. Although many diagnostic tissue-based biomarkers have been described to correlate with prognosis, n...
- Health & MedicineOpen access
Abstract Recently venetoclax (Ven) monotherapy showed promising efficacy for relapsed/refractory (R/R) Waldenström macroglobulinemia (WM), a population with significant medical unmet need. We report the efficacy and safety of Ven associated or not with anti-CD20 therapy, in a rea...
- Health & MedicineOpen access
BACKGROUND AND PURPOSE: High-tech medical resources play an increasingly important role in cancer diagnosis and treatment. However, accessing information about these technologies remains challenging due to their complexity and a lack of clear information pathways to obtain reliab...
- Health & MedicineOpen access
Summary Using LYmphoma Study Association clinical trials combining 438 first‐line large B‐cell lymphomas (LBCL) patients >80 years old, we defined SENIOR‐IPI, an easily applicable prognostic index for this elderly population treated with an anti‐CD20‐miniCHOP (cyclophosphamide, d...
- AI & ComputingOpen access
Semi-parametric modelling for analysing the evolution of toxicities over time
In oncology clinical research, reporting adverse events (AEs) is absolutely essential to depict the toxicity profile of new therapeutics such as targeted therapies or immunotherapies. However, conventional methods of analysis are unable to capture the new patterns of AEs induced...
- BiologyOpen access
Large B cell lymphomas (LBCLs) exhibit significant heterogeneity which leads to disparate treatment response, with up to 40% of patients developing refractory disease or relapsing within the first two years. To understand the cellular and molecular basis of this heterogeneity, we...
- Health & MedicineOpen access
Abstract In previous analyses of MAIA, daratumumab plus lenalidomide/dexamethasone (D-Rd) significantly improved progression-free survival and overall survival (OS) versus lenalidomide/dexamethasone (Rd) in transplant-ineligible newly diagnosed multiple myeloma (NDMM). We report...